Daily non-political popular news in brief.

Dual gene therapy suppresses lung cancer in preclinical test

Combination gene therapy delivered in lipid-based nanoparticles drastically reduces the number and size of human non-small cell lung cancer tumors in mice, researchers at The University of Texas M. D. Anderson Cancer Center and the University of Texas Southwestern Medical Center report in the January 15 edition of Cancer Research.

Read more »

Keywords: dual, gene, therapy, suppresses, lung, cancer, preclinical, test, suppresse

« Previous | Next »

Similar news on "Dual gene therapy suppresses lung cancer in preclinical test":

1. Modeling lung cancer
   02-12-2007 · EurekAlert!
   In a new report in the February 15 issue of G&D, Dr. Martin McMahon and colleagues present a novel mouse model of non-small cell lung cancer, which will serve as a useful tool to test the efficacy of novel chemotherapeutic drug therapies in the early stages of lung tumorigenesis. Their paper provides evidence to support the use of a relatively new class of drugs, called MEK inhibitors, for lung cancer patients whose tumors contain mutations in the BRaf gene.
   Similar news · Read more »
   
2. M. D. Anderson researchers identify tumor-suppressor gene for lung cancer
   11-13-2007 · EurekAlert!
   The GPRC5A gene, which is under-expressed in human lung cancer cells, suppresses lung tumors in mouse models and could provide a key to attacking lung cancer in humans, researchers at the University of Texas M. D. Anderson Cancer Center report in the Nov. 21 edition of the Journal of the National Cancer Institute.
   Similar news · Read more »
   
3. Pre-treatment blood test could guide lung cancer therapy
   06-05-2007 · EurekAlert!
   A multi-center team, led by Vanderbilt-Ingram Cancer Center investigators, has developed a new pre-treatment blood test that predicts which non-small-cell lung cancer patients will live longer when they are treated with certain targeted cancer therapies (Iressa, Tarceva). The mass spectrometry-based test, described in the June 6 Journal of the National Cancer Institute, may allow physicians to select the most beneficial therapy for each lung cancer patient, a step forward in the era of personalized medicine.
   Similar news · Read more »
   
4. Intravenous nanoparticle gene therapy shows activity in stage IV lung cancer
   04-17-2007 · EurekAlert!
   A cancer-suppressing gene has been successfully delivered into the tumors of stage four lung cancer patients via an intravenously administered lipid nanoparticle in a phase I clinical trial at the University of Texas M. D. Anderson Cancer Center. The gene, FUS1, also was found to be active in the metastatic nonsmall cell lung cancer tumors.
   Similar news · Read more »
   
5. Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer
   09-25-2007 · EurekAlert!
   Researchers have found that the breast cancer susceptibility gene, BRCA1, plays a significant role in nonsmall cell lung cancer. They told the European Cancer Conference in Barcelona that not only can it be used to predict outcome for patients with NSCLC, but it may also prove to be a valuable tool in choosing the best therapy for them.
   Similar news · Read more »
   
6. Gene therapy eradicates pancreatic cancer in preclinical trial
   07-09-2007 · EurekAlert!
   A molecularly engineered therapy selectively embeds a gene in pancreatic cancer that shrinks or eradicates tumors, inhibits metastasis, and prolongs survival with virtually no toxicity, researchers from The University of Texas M. D. Anderson Cancer Center report in the July 9 edition of Cancer Cell.
   Similar news · Read more »
   
7. Simple diagnostic test detects genetic signs of lung cancer in a patient's sputum
   01-18-2007 · EurekAlert!
   DNA coughed up along with phlegm could point to lung cancer, say researchers at the University of Maryland School of Medicine who are developing an inexpensive and non-invasive gene probe to help diagnose early stage lung cancer in current and former smokers.
   Similar news · Read more »
   
8. Gene therapy, cancer-killing viruses and new drugs highlight novel approaches to cancer treatment
   04-17-2007 · EurekAlert!
   Studies presented at the 2007 meeting of the American Association for Cancer Research show how researchers are using the new, as well as the natural, to help design and test new drugs to treat cancer.
   Similar news · Read more »
   
9. Growth factor signals influence balance between normal growth and cancerous growth
   11-09-2006 · EurekAlert!
   Too much of a signaling protein called insulin-like growth factor-I (IGF-I) may fan the flames of cancer, while too little of the protein may cause short stature, dementia and osteoporosis. New research investigates how the growth hormone/IGF system is affected by the important tumor suppressor gene p53. This interplay of two signaling pathways reinforces questions about the long-term risks of prescribing growth hormone, while suggesting a future new avenue for cancer therapy.
   Similar news · Read more »
   
10. Gene variations point to why lung cancer drugs work better in Japanese vs. US patients
    06-02-2007 · EurekAlert!
    Recent clinical trials revealed that Japanese lung cancer patients survived longer and had a higher rate of side effects than US patients taking the same two drugs, paclitaxel and carboplatin. Now a new study by the Southwest Oncology Group uncovers genetic differences that may explain why. The results, embargoed for release 8:30 a.m. ET Saturday, June 2, are being highlighted at the American Society of Clinical Oncology annual meeting.
    Similar news · Read more »